MB Author Contributions Found at: doi:10.1371/journal.pone.0010966.s002 (0.10 DOCX) Acknowledgments We are grateful to Joan Brugge for helpful discussions. References 1. Vaupel P, Mayer A (2007) Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225–239. 2. Zhang X, Gaspard JP, Chung DC (2001) Regulation of vascular endothelial growth factor by the Wnt and K-Ras pathways in colonic neoplasia. Cancer Res 61: 6050–6054. 3. Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, et al. (2005) Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11: 992–997. 4. Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, et al. (2006) Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 281: 13957–13963. 5. Boguski MS, Mccormick F (1993) Proteins regulating ras and its relatives. Nature 366: 643–654. 6. Berra E, Pages G, Pouyssegur J (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19: 139–145. 7. Blancher C, Moore JW, Robertson N, Harris AL (2001) Effects of RAS and Von Hippel Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 39-kinase/Akt signaling pathway. Cancer Res 61: 7349–7355. 8. Xu L, Pathak PS, Fukumura D (2004) Hypoxia-induced activation of p38 mitogen activated protein kinase and phosphatidylinositol 39-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res 10: 701–707. 9. Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, et al. (2005) Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24: 6555–6563. 10. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differenti- ation and tumor progression in the colon. Nat Genet 40: 600–608. 11. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, et al. (2007) Translational up regulation of the EGFR by tumor hypoxia provides a non mutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A 104: 13092–13097. 12. Wu W, Graves LM, Gill GN, Parsons SJ, Samet JM (2002) Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. J Biol Chem 277: 24252–24257. Hypoxic Activation of K-Ras Conceived and designed the experiments: MZ DCC. Performed the experiments: MZ. Analyzed the data: MZ MSP DCC. Contributed reagents/materials/analysis tools: MZ HK MSP. Wrote the paper: MZ MSP DCC. 13. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967–975. 14. Giaccia AJ, Simon MC, Johnson R (2004) The biology of hypoxia: The role of oxygen sensing in development, normal function, and disease. Genes Dev 18: 2183–2194. 15. Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12–16. 16. Sodhi A, Montaner S, Miyazaki H, Gutkind JS (2001) MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun 287: 292–300. 17. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, et al. (2004) Hypoxia- inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 64: 1765–1772. 18. Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, et al. (2009) Activation of src and src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J Cancer 124: 280–286. 19. Lei H, Kazlauskas A (2009) Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem 284: 6329–6336. 20. Wang Y, Roche O, Yan MS, Finak G, Evans AJ, et al. (2009) Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 15: 319–324. 21. Cox AD, Der CJ (2003) The dark side of Ras: Regulation of apoptosis. Oncogene 22: 8999–9006. 22. Cho DH, Lee HJ, Kim HJ, Hong SH, Pyo JO, et al. (2007) Suppression of hypoxic cell death by APIP-induced sustained activation of AKT and ERK1/2. Oncogene 26: 2809–2814. 23. Jiang Z, Zhang Y, Chen X, Lam PY, Yang H, et al. (2002) Activation of ERK1/ 2 and AKT in astrocytes under ischemia. Biochem Biophys Res Commun 294: 726–733. 24. Lee SM, Lee CT, Kim YW, Han SK, Shim YS, et al. (2006) Hypoxia confers protection against apoptosis via PI3K/AKT and ERK pathways in lung cancer cells. Cancer Lett 242: 231. 25. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, et al. (2009) KRAS/ BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8: 834–843. 26. Singh A, Sowjanya AP, Ramakrishna G (2005) The wild-type Ras: Road ahead. Faseb J 19: 161–169. PLoS ONE | www.plosone.org 11 June 2010 | Volume 5 | Issue 6 | e10966